Investor Relations
Corporate Profile
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
- Change
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Apr 09
2024
2024
Allogene Therapeutics Announces Q2 Investor Conference Participation
Learn More >
Mar 14
2024
2024
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Learn More >
Mar 12
2024
2024
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Learn More >
Mar 05
2024
2024
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Learn More >
Feb 28
2024
2024
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Learn More >
Feb 16
2024
2024
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Learn More >
Jan 16
2024
2024
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Learn More >
Jan 04
2024
2024
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Learn More >
Jan 04
2024
2024
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Learn More >
Jan 03
2024
2024
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
Learn More >